CJC-1295 w/ DAC

CJC-1295 w/ DAC is a modified, long-acting growth hormone-releasing hormone (GHRH) analog incorporating a Drug Affinity Complex (DAC). The DAC modification is designed to support prolonged activity through albumin binding, making CJC-1295 w/ DAC a research compound of interest in studies of sustained growth hormone signaling.

The material is supplied as a lyophilized powder with ≥99% HPLC purity and is intended exclusively for laboratory research.

Understanding CJC-1295 w/ DAC

CJC-1295 w/ DAC is a modified GHRH(1-29) analog incorporating a Drug Affinity Complex attachment.

The key distinction is the DAC component. Research into this modified form focuses on how the added complex influences the compound's persistence and interaction with albumin, resulting in a longer-acting research profile than shorter-acting GHRH analogs.

Because of this extended profile, CJC-1295 w/ DAC is commonly investigated in experimental systems examining sustained growth hormone secretion and growth hormone-axis signaling.

At a glance

Specification	Details
Product	CJC-1295 w/ DAC
CAS Number	446262-90-4
Molecular description	Modified GHRH analog with Drug Affinity Complex (DAC)
Approx. molar mass	~5 kDa range (core + DAC)
Structure	Modified GHRH(1-29) analog with DAC attachment
Synonyms	CJC-1295 with DAC; DAC:GRF
Purity	≥99% (HPLC)
Physical form	Lyophilized powder
Long-term storage	−20°C (−4°F)
After reconstitution	2–8°C (36–46°F)
Listed solvent	Bacteriostatic water for laboratory use
Intended use	Laboratory research only

Why is the DAC important?

The Drug Affinity Complex is the feature that distinguishes this version of CJC-1295 from a conventional short-acting GHRH analog.

Research examines the DAC modification in relation to albumin binding and prolonged activity. This makes the compound particularly relevant to experimental designs where researchers want to examine more sustained growth hormone signaling rather than a brief exposure.

Studies have investigated resulting changes in growth hormone secretion profiles and downstream IGF-1-related signaling in laboratory models.

Research applications

CJC-1295 w/ DAC is investigated primarily in studies involving the growth hormone axis.

Areas of research include:

• GHRH receptor signaling: Examination of signaling associated with GHRH-mediated growth hormone release.
• Growth hormone secretion: Experimental assessment of GH secretion following exposure to a long-acting GHRH analog.
• Sustained hormone signaling: Research into prolonged GH-related activity associated with the DAC modification.
• Albumin-binding research: Investigation of how DAC-associated albumin binding contributes to the compound's extended research profile.
• IGF-1 pathway research: Studies examining downstream signaling associated with growth hormone activity.
• Metabolic research: Experimental investigation of growth hormone-axis signaling in metabolic research models.

These applications describe laboratory and preclinical research. They do not establish CJC-1295 w/ DAC as a treatment, bodybuilding product, or human growth hormone enhancement product.

What distinguishes CJC-1295 w/ DAC?

The defining characteristic is the combination of a modified GHRH(1-29) analog with a Drug Affinity Complex.

Rather than simply identifying the compound by its GHRH activity, researchers evaluating CJC-1295 w/ DAC should consider the DAC modification as an important part of its molecular and pharmacological profile.

The supplied material is also specified at ≥99% HPLC purity and provided in lyophilized form, with a reported molecular mass in the ~5 kDa range for the core plus DAC.

Product quality and identification

For researchers comparing CJC-1295 DAC materials, accurate identification is important.

The supplied product information specifies:

• CAS: 446262-90-4
• Purity: ≥99% HPLC
• Form: Lyophilized powder
• Structure: Modified GHRH(1-29) analog with DAC attachment
• Synonyms: CJC-1295 with DAC; DAC:GRF

These identifiers provide a practical starting point for comparing research materials and confirming that the compound matches the requirements of a laboratory protocol.

Storage and laboratory handling

CJC-1295 w/ DAC is supplied as a lyophilized powder. The supplied specifications indicate storage at −20°C (−4°F) for long-term storage and 2–8°C (36–46°F) after reconstitution.

Bacteriostatic water for laboratory use is listed as the solvent.

Researchers should use the product documentation and established laboratory procedures when preparing, storing, and handling the material. Preparation conditions should be selected according to the requirements of the specific research protocol.

Before you order CJC-1295 w/ DAC

If you are comparing a CJC-1295 DAC supplier or looking for a CJC-1295 research peptide, focus on the actual specifications rather than marketing terminology.

The DAC designation is particularly important because it identifies the long-acting modified form. Researchers should confirm the product name, CAS number, molecular description, purity, physical form, and storage requirements before selecting a research material.

This product is intended for laboratory research only and is not intended for human or veterinary use.

Frequently asked questions

What is CJC-1295 w/ DAC?

CJC-1295 w/ DAC is a modified GHRH analog incorporating a Drug Affinity Complex. It is studied in laboratory research involving prolonged growth hormone-axis signaling and GH secretion.

What does DAC mean in CJC-1295 w/ DAC?

DAC refers to the Drug Affinity Complex incorporated into the modified GHRH analog. Research examines its relationship with albumin binding and the compound's prolonged activity.

What is CJC-1295 w/ DAC studied for?

Research focuses on GHRH-mediated growth hormone secretion, sustained GH signaling, albumin-binding behavior, and related IGF-1 and metabolic pathways.

What is the CAS number for CJC-1295 w/ DAC?

The supplied CAS number is 446262-90-4.

What is the purity of CJC-1295 w/ DAC?

The specified purity is ≥99% by HPLC.

What form is CJC-1295 w/ DAC supplied in?

It is supplied as a lyophilized powder.

What is the approximate molecular mass?

The supplied specification gives an approximate molar-mass range of ~5 kDa for the core plus DAC.

What is the listed sequence?

The supplied information describes it as a modified GHRH(1-29) analog with Drug Affinity Complex attachment rather than providing a complete residue-level sequence.

How should CJC-1295 w/ DAC be stored?

The supplied specifications list −20°C (−4°F) for long-term storage and 2–8°C (36–46°F) after reconstitution.

What solvent is listed for reconstitution?

Bacteriostatic water for laboratory use is listed in the supplied product specifications.

Is CJC-1295 w/ DAC intended for human use?

No. This product is intended for laboratory research only and is not for human or veterinary consumption.

Product summary

CJC-1295 w/ DAC is a modified GHRH analog incorporating a Drug Affinity Complex and is studied for its prolonged growth hormone-axis activity and albumin-binding characteristics.

Supplied as a lyophilized powder with ≥99% HPLC purity, the material is identified by CAS number 446262-90-4 and described as a modified GHRH(1-29) analog with DAC attachment.

For laboratories researching GHRH signaling, growth hormone secretion, sustained hormonal activity, or related metabolic pathways, the defined molecular description, purity specification, physical form, and storage information provide the key details needed for research-material evaluation.

For laboratory research only. Not for human or veterinary consumption.